Cargando…

Risk model in stage IB1-IIB cervical cancer with positive node after radical hysterectomy

The purpose of this study was to identify risk factors in patients with surgically treated node-positive IB1-IIB cervical cancer and to establish a risk model for disease-free survival (DFS) and overall survival (OS). A total of 170 patients who underwent radical hysterectomy and bilateral pelvic ly...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhilan, Huang, Kecheng, Lu, Zhiyong, Deng, Song, Xiong, Jiaqiang, Huang, Jia, Li, Xiong, Tang, Fangxu, Wang, Zhihao, Sun, Haiying, Wang, Lin, Zhou, Shasha, Wang, Xiaoli, Jia, Yao, Hu, Ting, Gui, Juan, Wan, Dongyi, Ma, Ding, Li, Shuang, Wang, Shixuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892859/
https://www.ncbi.nlm.nih.gov/pubmed/27313462
http://dx.doi.org/10.2147/OTT.S94151
Descripción
Sumario:The purpose of this study was to identify risk factors in patients with surgically treated node-positive IB1-IIB cervical cancer and to establish a risk model for disease-free survival (DFS) and overall survival (OS). A total of 170 patients who underwent radical hysterectomy and bilateral pelvic lymphadenectomy as primary treatment for node-positive International Federation of Gynaecology and Obstetrics (FIGO) stage IB1-IIB cervical cancer from January 2002 to December 2008 were retrospectively analyzed. Five published risk models were evaluated in this population. The variables, including common iliac lymph node metastasis and parametrial invasion, were independent predictors of outcome in a multivariate analysis using a Cox regression model. Three distinct prognostic groups (low, intermediate, and high risk) were defined using these variables. Five-year DFS rates for the low-, intermediate-, and high-risk groups were 73.7%, 60.0%, and 25.0%, respectively (P<0.001), and 5-year OS rates were 81.9%, 42.8%, and 25.0%, respectively (P<0.001). The risk model derived in this study provides a novel means for assessing prognosis of patients with node-positive stage IB1-IIB cervical cancer. Future study will focus on external validation of the model and refinement of the risk scoring systems by adding new biologic markers.